Core Insights - Senti Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [1][2] - The company aims to create therapies that can precisely target and kill cancer cells while sparing healthy cells, enhancing specificity to target tissues, and allowing for control even after administration [2] Company Overview - Senti Bio is leveraging synthetic biology to engineer Gene Circuits into new medicines aimed at treating patients with incurable diseases [2] - The company's pipeline includes cell therapies designed to target challenging liquid and solid tumor indications, with preclinical evidence supporting the efficacy of Gene Circuits in both NK and T cells [2] - Senti Bio is also exploring the potential applications of Gene Circuits in other modalities and diseases beyond oncology through partnerships [2] Event Participation - Timothy Lu, M.D., Ph.D., Co-Founder and CEO of Senti Bio, participated in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference, sharing insights into his dedication to the company and its programs [1][2]

Company Overview - Senti Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [3] - The company aims to create new medicines that can precisely target and kill cancer cells while sparing healthy cells, enhancing specificity to target tissues, and allowing for control even after administration [3] Upcoming Event - Timothy Lu, M.D., Ph.D., Co-Founder and CEO of Senti Bio, will present at the LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar on May 29, 2025, at 2:40 PM ET [1][2] Technology and Pipeline - Senti Bio's pipeline includes cell therapies engineered with Gene Circuits targeting challenging liquid and solid tumor indications [3] - The Gene Circuits have shown preclinical efficacy in both NK and T cells, with potential applications extending beyond oncology [3]

Company Overview - Senti Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [1][5] - The company aims to create therapies with enhanced precision and control to treat patients with incurable diseases [5] Leadership Appointment - Feng Hsiung has been appointed to the Board of Directors, effective March 7, 2025, bringing extensive experience in investment strategy and capital markets [2][3] - Hsiung is the Founder, Chief Investment Officer, and CEO of Acion Partners, with a background that includes leadership roles at York Capital [2] Stock Options Grant - On March 7, 2025, the Board granted stock options to three new employees, totaling 202,700 shares at an exercise price of $3.52 per share [4] - The majority of these options, 174,200, were awarded to the new Chief Financial Officer, Jay Cross, under the 2022 Inducement Equity Plan [4] Product Pipeline - Senti Bio's lead program, SENTI-202, targets hematologic cancers and has shown promising initial clinical data, with two out of three patients achieving MRD-negative complete remissions [5] - The company is also advancing its Gene Circuits technology in T cells and exploring applications beyond oncology [5]